Sanglodkar Uday, Jain Mayank, Vargese Joy, Kedarisetty Chandankumar, Venkataraman Jayanthi
Global Health City, India.
SRIHER, Chennai, India.
Clin Exp Hepatol. 2019 Nov;5(4):301-307. doi: 10.5114/ceh.2019.88774. Epub 2019 Oct 16.
The recommended high dose albumin treatment for spontaneous bacterial peritonitis (SBP) is not possible in the Indian setting due to financial constraints. Aim of the study was the retrospective audit to determine the outcome of patients with SBP on combination treatment of low dose albumin and appropriate antibiotics.
Patients undergoing abdominal paracentesis in the period 2016-2018 were included. Patient details including age, gender, co-morbidity profile, details of previous hospitalisation and antibiotics, MELD score, and ascitic fluid analysis were noted. Details of albumin use and antibiotics were retrieved. SBP was classified based on mode of acquisition of infection and severity risk based on laboratory parameters. Statistics - χ test, Mann-Whitney test, relative risk calculation. A value of < 0.05 was considered as significant.
24 (18.8%), 38 (29.7%) and 66 patients (51.5%) belonged to low, intermediate and high risk SBP groups, respectively. The median dose of albumin was 20 g/day for a median duration of 5 days (range 1-8). Between the 3 subgroups, there was no significant difference in the median age; the majority were men. Antibiotic escalation was necessary in intermediate and high risk cases (42.1% vs. 84.8%, < 0.0001). The mortality rate in intermediate and high risk groups was 29% and 42%, respectively ( = 0.18). Between the 2 subgroups of intermediate risk, patients with serum bilirubin < 4 mg/dl and serum creatinine > 1 mg/dl were significantly older (54 vs. 49 years, = 0.02), and had high mortality (40.7% vs. 0%). Cirrhosis-related complications (CRC; one or more in combinations) were more frequent in high risk and intermediate risk patients ( = 0.001) with a 7-8 times higher risk of mortality compared to those who had no CRC.
Our protocol is associated with high mortality in intermediate and high risk SBP patients. Presence of one or more CRC increases the risk of mortality several fold.
由于经济限制,在印度无法采用推荐的高剂量白蛋白治疗自发性细菌性腹膜炎(SBP)。本研究的目的是进行回顾性审计,以确定低剂量白蛋白与适当抗生素联合治疗SBP患者的结局。
纳入2016年至2018年期间接受腹腔穿刺术的患者。记录患者的详细信息,包括年龄、性别、合并症情况、既往住院和使用抗生素的详情、终末期肝病模型(MELD)评分以及腹水分析结果。获取白蛋白使用情况和抗生素的详细信息。根据感染获得方式对SBP进行分类,并根据实验室参数对严重程度风险进行分类。统计学方法——χ检验、曼-惠特尼检验、相对风险计算。P值<0.05被认为具有统计学意义。
24例(18.8%)、38例(29.7%)和66例患者(51.5%)分别属于低、中、高风险SBP组。白蛋白的中位剂量为20克/天,中位持续时间为5天(范围1 - 8天)。在这3个亚组之间,中位年龄无显著差异;大多数为男性。中、高风险病例需要升级抗生素治疗(42.1%对84.8%,P<0.0001)。中、高风险组的死亡率分别为29%和42%(P = 0.18)。在中度风险的2个亚组中,血清胆红素<4毫克/分升且血清肌酐>1毫克/分升的患者年龄显著更大(54岁对49岁,P = 0.02),且死亡率更高(40.7%对0%)。与无肝硬化相关并发症(CRC;一种或多种组合)的患者相比,高风险和中度风险患者的CRC更常见(P = 0.001),死亡风险高7 - 8倍。
我们的方案与中、高风险SBP患者的高死亡率相关。存在一种或多种CRC会使死亡风险增加数倍。